Jing Wan

Title: Jing Wan: Innovator in Cancer Treatment

Introduction

Jing Wan is a prominent inventor based in Chapel Hill, NC (US), known for his significant contributions to cancer treatment through innovative methodologies. With a total of 2 patents, his work focuses on the development of therapeutic strategies that target specific cancer pathways.

Latest Patents

Jing Wan's latest patents include a method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor. This invention provides combinations comprising a MERTK inhibitor, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor, along with methods of use for treating disorders such as cancer. Another notable patent involves soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease. This patent details soluble epidermal growth factor receptors 2 and 3 (HER2 and HER3) splice variant proteins with antagonist activity and anti-proliferative properties, as well as the corresponding nucleic acids for the treatment of proliferative diseases, particularly cancer.

Career Highlights

Jing Wan has worked at esteemed institutions such as the University of North Carolina at Chapel Hill and Emory University. His research has significantly advanced the understanding and treatment of cancer, showcasing his dedication to improving patient outcomes through innovative solutions.

Collaborations

Jing Wan has collaborated with notable colleagues, including Dan Yan and H Shelton Earp, III. These partnerships have fostered a collaborative environment that enhances research and development in the field of cancer treatment.

Conclusion

Jing Wan's contributions to cancer treatment through his innovative patents and collaborations highlight his role as a leading inventor in the medical field. His work continues to pave the way for advancements in therapeutic strategies against cancer.